Treats mild/moderate type 1 Gaucher disease. ANDA 219111, held by Navinta LLC. Miglustat.
As of Nov 16, 2026, ANDA 219111 (Miglustat), held by Navinta LLC, was first approved by FDA on Mar 14, 2025, with 0 approved supplements and 0 published complete response letters.
Miglustat is a glucosylceramide synthase inhibitor indicated as monotherapy for treatment of adult patients with mild/moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option. 1.1 Type 1 Gaucher Disease Miglustat is indicated as monotherapy for the treatment of adult patients with mild to moderate type 1 Gaucher disease for whom enzyme replacement therapy is not a therapeutic option (e.g. due to allergy, hypersensitivity, or poor venous access).
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 14, 2025 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Miglustat100MG · capsule;oral | Miglustat | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters